KR20200038553A - 약제의 제조 방법 - Google Patents

약제의 제조 방법 Download PDF

Info

Publication number
KR20200038553A
KR20200038553A KR1020207009606A KR20207009606A KR20200038553A KR 20200038553 A KR20200038553 A KR 20200038553A KR 1020207009606 A KR1020207009606 A KR 1020207009606A KR 20207009606 A KR20207009606 A KR 20207009606A KR 20200038553 A KR20200038553 A KR 20200038553A
Authority
KR
South Korea
Prior art keywords
chloro
methyl
fluorophenyl
pyrimidin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207009606A
Other languages
English (en)
Korean (ko)
Inventor
진광 린
알렉산드라 체스타코바
웨이 구
한스 이딩
징 리
신 링후
패트릭 마이어
춘보 사
제프리 스툴츠
유추 왕
하이밍 장
지안쳰 장
타오 장
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Priority to KR1020227045548A priority Critical patent/KR20230006043A/ko
Publication of KR20200038553A publication Critical patent/KR20200038553A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR1020207009606A 2014-04-09 2015-04-08 약제의 제조 방법 Ceased KR20200038553A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227045548A KR20230006043A (ko) 2014-04-09 2015-04-08 약제의 제조 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
CNPCT/CN2014/075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030901A Division KR102490955B1 (ko) 2014-04-09 2015-04-08 약제의 제조 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045548A Division KR20230006043A (ko) 2014-04-09 2015-04-08 약제의 제조 방법

Publications (1)

Publication Number Publication Date
KR20200038553A true KR20200038553A (ko) 2020-04-13

Family

ID=54287327

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207009606A Ceased KR20200038553A (ko) 2014-04-09 2015-04-08 약제의 제조 방법
KR1020227045548A Abandoned KR20230006043A (ko) 2014-04-09 2015-04-08 약제의 제조 방법
KR1020167030901A Active KR102490955B1 (ko) 2014-04-09 2015-04-08 약제의 제조 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227045548A Abandoned KR20230006043A (ko) 2014-04-09 2015-04-08 약제의 제조 방법
KR1020167030901A Active KR102490955B1 (ko) 2014-04-09 2015-04-08 약제의 제조 방법

Country Status (22)

Country Link
US (4) US20170022183A1 (OSRAM)
EP (2) EP3494971B1 (OSRAM)
JP (3) JP6723926B2 (OSRAM)
KR (3) KR20200038553A (OSRAM)
CN (3) CN106659721B (OSRAM)
AR (1) AR099989A1 (OSRAM)
AU (2) AU2015245743B2 (OSRAM)
BR (2) BR122020014933B8 (OSRAM)
CA (2) CA2945098C (OSRAM)
ES (1) ES2733495T3 (OSRAM)
HR (1) HRP20191306T1 (OSRAM)
IL (2) IL248205B (OSRAM)
MX (2) MX392460B (OSRAM)
MY (3) MY188526A (OSRAM)
NZ (1) NZ725450A (OSRAM)
PL (1) PL3129025T3 (OSRAM)
RU (1) RU2684102C2 (OSRAM)
SG (1) SG11201608421XA (OSRAM)
SI (1) SI3129025T1 (OSRAM)
TW (2) TWI678366B (OSRAM)
WO (1) WO2015154674A1 (OSRAM)
ZA (1) ZA201607066B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015085007A1 (en) 2013-12-06 2015-06-11 Genentech, Inc. Serine/threonine kinase inhibitors
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments
HRP20200342T1 (hr) 2015-11-09 2020-06-12 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni u liječenju raka
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
IL293382A (en) * 2019-12-05 2022-07-01 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2205086B1 (en) * 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
MY188526A (en) * 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
US20190367484A1 (en) 2019-12-05
CN111777594B (zh) 2023-06-27
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
US20180134685A1 (en) 2018-05-17
CA2945098C (en) 2022-10-04
US11066389B2 (en) 2021-07-20
EP3129025A4 (en) 2018-01-17
EP3129025A1 (en) 2017-02-15
US20200190061A1 (en) 2020-06-18
EP3129025B1 (en) 2019-05-15
PL3129025T3 (pl) 2019-11-29
KR20230006043A (ko) 2023-01-10
MY188526A (en) 2021-12-18
ES2733495T3 (es) 2019-11-29
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
CN112645927A (zh) 2021-04-13
MX2020010384A (es) 2022-05-19
JP2020114817A (ja) 2020-07-30
CN106659721B (zh) 2021-01-01
NZ725450A (en) 2022-08-26
MX2016013162A (es) 2017-04-27
SG11201608421XA (en) 2016-11-29
BR122020014933B8 (pt) 2022-12-13
IL268690A (en) 2019-10-31
AU2020220208B2 (en) 2022-03-17
KR102490955B1 (ko) 2023-01-19
TWI762806B (zh) 2022-05-01
EP3494971C0 (en) 2024-07-24
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
SI3129025T1 (sl) 2019-08-30
AU2015245743A1 (en) 2016-10-27
BR112016023391A8 (pt) 2018-04-17
US20170022183A1 (en) 2017-01-26
ZA201607066B (en) 2018-05-30
IL248205A0 (en) 2016-11-30
TW201620897A (zh) 2016-06-16
MY196320A (en) 2023-03-24
WO2015154674A1 (en) 2015-10-15
RU2016139286A3 (OSRAM) 2018-10-26
US11098028B2 (en) 2021-08-24
JP6723926B2 (ja) 2020-07-15
CN111777594A (zh) 2020-10-16
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
CN106659721A (zh) 2017-05-10
BR112016023391A2 (OSRAM) 2017-08-15
EP3494971A1 (en) 2019-06-12
JP6974524B2 (ja) 2021-12-01
TWI678366B (zh) 2019-12-01
EP3494971B1 (en) 2024-07-24
BR112016023391B1 (pt) 2022-08-09
RU2684102C2 (ru) 2019-04-04
AU2015245743B2 (en) 2020-09-24
HRP20191306T1 (hr) 2019-10-18
RU2016139286A (ru) 2018-05-15
JP2017510620A (ja) 2017-04-13
AU2020220208A1 (en) 2020-09-10
AR099989A1 (es) 2016-08-31
JP2021167321A (ja) 2021-10-21
TW201945358A (zh) 2019-12-01
MX375638B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
US11098028B2 (en) Process for the manufacturing of medicaments
HK40039714B (zh) 用於制备药物的方法
HK40007970A (en) Salts of erk inhibitors
HK40039714A (en) Process for the manufacturing of medicaments
HK40007970B (en) Salts of erk inhibitors
CN116813608B (zh) 噻唑类化合物及其应用
HK1233931A1 (en) Process for the manufacturing of medicaments
HK1233931B (en) Process for the manufacturing of medicaments
NZ761260A (en) Crystalline salts of erk inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200402

Application number text: 1020167030901

Filing date: 20161104

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210926

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220606

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210926

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220606

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220225

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220923

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220907

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220606

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220225

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210926